Plasmin therapy enhances mobilization of HPCs after G-CSF

Blood. 2008 Nov 15;112(10):4048-50. doi: 10.1182/blood-2008-07-166587. Epub 2008 Aug 22.

Abstract

The role of proteinases in the mobilization of hematopoietic progenitor cells (HPCs) after granulocyte colony-stimulating factor (G-CSF) remains unclear. Here we report that genetic loss of the plasminogen activator inhibitor Pai-1 or of the plasmin inhibitor alpha2-antiplasmin increases HPC mobilization in response to G-CSF. Moreover, thrombolytic agents, such as tenecteplase and microplasmin, enhance HPC mobilization in mice and humans. Taken together, these findings identify a novel role for plasmin in augmenting HPC mobilization in response to G-CSF.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Female
  • Fibrinolysin / administration & dosage*
  • Fibrinolytic Agents / administration & dosage*
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cells / cytology*
  • Humans
  • Male
  • Mice
  • Peptide Fragments / administration & dosage
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Serpin E2
  • Serpins / genetics
  • Serpins / metabolism
  • Tenecteplase
  • Tissue Plasminogen Activator / administration & dosage
  • alpha-2-Antiplasmin / genetics
  • alpha-2-Antiplasmin / metabolism

Substances

  • Fibrinolytic Agents
  • Peptide Fragments
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human
  • Serpin E2
  • Serpine2 protein, mouse
  • Serpins
  • alpha-2-Antiplasmin
  • Granulocyte Colony-Stimulating Factor
  • microplasmin
  • Tissue Plasminogen Activator
  • Fibrinolysin
  • Tenecteplase